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Experimental  evidence  has  been  accumulated  which  suggests  a  possible 
relationship  between  autoimmunity and  neoplasia.  Approximately  25%  of 
NZB mice, a strain which spontaneously develops lethal autoimmune disease, 
also develop lymphoid neoplasias (1).  Human patients with Hodgkin's disease 
frequently  develop  antilymphocyte  autoantibodies  (2)  and  about  30%  of 
leukemia patients have detectable antibodies to their own red cells  (3).  More- 
over,  autoimmune  hemolytic anemia  is  a  frequent  complication  of  chronic 
lymphocytic leukemia  (4)  and  splenic lymphocytes from mice infected with 
Rauscher leukemia virus were reported to have mounted an immune response 
against erythrocytes from syngeneic mice (5).  The target cells of autoimmun- 
ity in neoplastic diseases are not only limited to lymphocytes and erythrocytes. 
Cytotoxic effects against normal adult glial cells have been reported in patients 
with  malignant  brain  tumors  (6).  Such  autoimmune  processes  might  well 
result in a generalized weakening of the host's immunosurveillance capabilities 
since it is known that immunosuppressed animals develop neoplasms in greater 
numbers than normal animals (7). 
The establishment of a  direct relationship beteen  autoimmunity and  neo- 
plasia would require the demonstration of an experimentally induced, tumor- 
dependent autoimmune process.  We have studied  cellular immune reactions 
of mice  with  the  aim  of detecting possible  autoimmune-like reactions  asso- 
ciated with the presence of a  transplantable L1210 leukemia. 
Materials and Methods 
Animals.--Female  mice of the inbred strains DBA/2  (H-2  a)  and  C57B1/6  (H-2  b)  and 
their F1 hybrid, BDF1, were obtained from Jackson Laboratories, Bar Harbor, Maine. 
Tumor Cell Line.--L1210  ascitic leukemic cells,  which are of DBA/2 origin,  were main- 
tained by passage in BDF1 mice. Recipient mice were injected i.p. with 105 L1210  cells in a 
volume of 0.1 ml. 7-9 days later, ascitic fluid was withdrawn and 10  ~ cells were transferred 
to new recipient animals. Spleen cells from tumor-bearing mice were collected on the 7-9th 
day after tumor injection. 
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Mixed Lymphocyte Reaaions.--MLR's were performed according to  the method of Gazit 
and Harris  (8).  Spleen cells were cultured in RPMI  1640 medium supplemented with peni- 
cillin (50 U/ml), streptomycin (50/zg/ml) and L-glutamine (200 raM, 2  ml per 100 ml of me- 
dium). Mixed lymphocyte cultures contained 3  X  10  e cells of each type  (a total of 6  X  106 
cells) in 3  ml of medium. Control cultures contained 3  X  106 cells from either source, alone, 
in 3 ml of medium. Three replicates of each cell type or combination were done. After 3  days, 
1 ml of RPMI  1640 culture medium containing 1 #Ci/ml trifiated thymidine was added to 
each culture tube.  18-24 h  later, cultures were harvested with cold TCA, solubilized in NCS 
tissue solubilizer  (Amersham-Searle, Arlington Heights, Ill.),  dissolved in Liquifluor  (New 
England Nuclear  Corp.,  Boston, Mass.), and counted for  tritiated  thymidine incorporation 
in  a  liquid  scintillation  counter.  One-way mixed lymphocyte reactions were  performed  by 
treating cells with 25 or 50 #g/ml mitomycin-C for 30 rain at 37°C, washing twice, incubating 
for 10 min at 37°C, and washing again before placing the mitomycin-treated cells in culture. 
Results are recorded  as DPM  incorporated  per culture and as the ratio  (R)  of DPM  in 
mixed cultures divided  by the sum of DPM  in cultures of each cell type alone. A  ratio  of 
approximately 1 indicates that no significant reaction has occurred. A  ratio of approximately 
2  or more indicates a  significant reaction. 
RESULTS 
Normal  DBA/2  spleen  cells were  cultured with  spleen  cells from hybrid 
BDF1 mice bearing the L1210 tumor (BDFt) in a two-way MLR (experiment 
24, Table I). A surprisingly  high response  (> 100 DPM) resulted,  despite  the 
lack of response in cultures of normal DBA/2 cells and normal BDF1 cells in 
the  same  experiment.  We  hypothesized that  the  strong  response  was  due 
primarily to the reaction of the normal DBA/2  cells against the postulated 
TABLE  I 
Mixed Lymphocyte Reactivity of Spleen Cells from Tumor-Bearing Ft Mice Against  Normal 
Parental Cells 
Exper-  DPM 
iment  Combination  R§ 
no.  BDFt*  BDFtm:~  DBA  DBAm:~  BDF  MLR 
24  127,390  6,324 
6,324 
27  7,136  1,722 
3,928  1,722 
7,136 
28  5,934 
5,934 
32  21,963 
21,963 
33  5,247 
1,150 
3,638 
1,722  995 
6,901 
959  6,901 
1,371 
567 
194 
1,880 
3,727  1,880 
1,132,342  BDFt X DBA  8.5 
5,667  BDF X DBA  <1 
503,557  BDFt X DBA  56.8 
19,956  DBA X BDFtm  3.5 
87,845  BDFt X DBAm  10.6 
6,258  BDF X DBA  2.3 
373,024  BDFt X DBA  29.1 
13,007  DBA X BDFtm  1.7 
194,700  BDFt X DBAm  26.7 
743,932  BDFt X DBA  31.2 
10,150  DBA X BDFtm  1.8 
492,424  BDFt X DBAm  21.9 
40,204  BDFt vs. DBAm  7.4 
* Spleen cells from L1210-bearing BDFt mice. 
:~ Mitomycin-treated  spleen cells. 
§ Counts in mixed cultures divided by sum  of counts in cultures of each ceil type alone. 226  REACTION OF  1~1  CELLS  AGAINST PARENTAL CELLS 
tumor-specific antigens (TSA) present on the BDFt ceils. This hypothesis was 
tested  by  treating  BDFt  cells  or  normal  DBA/2  cells  with  mitomycin-C, 
before culturing them with untreated cells  (experiments 27,  28,  32,  and 33, 
Table I). Surprisingly, DBA/2 cells responded relatively weakly against mito- 
mycin-treated BDFt cells, whereas a very strong response was seen in all four 
experiments where BDFt cells were reacted against mitomycin-treated DBA/2 
cells.  Control cultures of normal BDF1 X  DBA/2 cells had approximately the 
same level of response as the DBA/2 X  BDFtm cultures, indicating that the 
H-2 antigens on the BDFt cells were not different from those on normal BDFI 
cells. It is apparent from these experiments that spleen cells from mice bearing 
the L1210 leukemic tumor were  able to mount a  very vigorous immune re- 
sponse  against  mitomycin-treated normal  cells  which  had  no  different H-2 
antigens than those on the reacting cells. 
The specificity of the response of BDFt cells in this system was examined by 
reacting the BDFt cells against parental C57B1/6 spleen cells  (i.e.,  the alter- 
nate parental strain  which does not share H-2  antigens with the  tumor cell 
line).  In  experiments 35  and 36  (Table  II),  it can be seen  that BDFt  cells 
failed to react against normal C57B1/6 cells.  As expected, however, the C57 
B1/6  cells  did  respond  significantly to  mitomycin-treated BDFt  cells,  and 
BDFt cells  responded vigorously to DBAm cells.  We concluded that the re- 
sponse reported in Table I  was immunologically specific in that it was directed 
against only normal cells of the same strain as the tumor cells,  i.e., DBA/2. 
As seen in Table I, BDFt cells responded much more vigorously to normal 
DBA/2 cells than did normal BDF1 cells. This comparison may not be valid, 
however, since cells from a tumor-beating animal had been exposed previously 
to  tumor  cells  of DBA/2  origin  and  were  presented  with DBA/2  antigens 
for the second time when they were cultured with DBA/2  spleen cells  in a 
MLR.  For  this  reason,  we  examined  the  effects of  injecting normal  BDF1 
mice  with  normal  DBA/2  spleen  cells  before  culturing  them  with  DBA/2 
cells  in MLR's (Table III). BDF1 mice were injected with varying amounts 
TABLE  II 
Mixed Lymphocyte Reactivity of Spleen Cells from  Tumor-Bearlng Pl Mice  against Normal 
Parental Cells 
Exper-  DPM 
iment  Combination  R§ 
no.  BDFt*  BDFtm$  C57B1/6  C57B1/6m$  DBA/2m$  MLR 
35  18,049  353  15,755  BDFt X  C57  <1 
1,339  353  3,382  C57 X  BDFtm  1.9 
18,049  178  10,231  BDFt X  C57m  <1 
36  5,468  149  4,585  BDFt X  C57m  <1 
5,468  618  120,056 BDFt X  DBAm  20.9 
* BDFt spleen  cells from L1210-bearing BDF1 mice. 
$ Mitomycin-treated spleen  cells. 
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TABLE  III 
Mixed Lymphocyte Reactivity of BDF1 Spleen Cdls from Mice Injected with  Parental Spleen 
Cells, against Normal Parental Spleen Cells 
DPM 
BDF.x*  BDF*I:~  BDFss§  BDFtU  DBAm¶  MLR 
Combination  R 
5,499 
2,549 
2,677 
5,247 
194  2,084  BDF.I* X  DBAm  <1 
194  2,376  BDF2x:~  X  DBAm  <1 
194  3,191  BDF~§ X  DBAm  1.1 
194  40,204  BDFt X  DBAm  7.4 
* BDFa spleen cells 7 days after i.p. injection of 0.1 X  10  e DBA/2 spleen cells. 
:~ BDFx spleen cells 7 days after i.p. injection of 21 X  106 DBA/2 spleen cells. 
§ BDFI spleen cells 7 days after i.p. injection of 85 X  l0  s DBA/2 spleen cells. 
II BDFI spleen cells from L1210 bearing mice. 
¶ Mitomycin-treated spleen cells. 
of normal DBA/2 spleen cells  7 days before harvesting the BDF~ spleen cells 
for MLR's. Injection of 0.1  X  106  DBA/2  spleen  cells  corresponded  to  the 
number  of L1210  cells  normally employed in  transferring the  tumor. Other 
mice were injected with 21  X  l0  s or 85  X  l0  s DBA/2 spleen cells.  It can be 
seen in Table III that none of the preinjection schedules resulted in a signifi- 
cant MLR when spleen cells from injected animals were reacted against nor- 
mal DBA/2  cells.  The response  of BDFt X  DBAm in the  same experiment 
was highly significant. It is obvious from these experiments that pre-exposure 
to  DBA/2  antigens was  not  responsible for  the  suggestive anfiself activity 
seen in cultures of BDFt X  DBAm cells. 
DISCUSSION 
The initial purpose of these experiments was to determine whether normal 
spleen  cells  would  react  in  MLR  against  semi-syngeneic  spleen  cells  from 
tumor-bearing  mice  (BDF1).  The  spleens  of L1210-bearing  mice  have  been 
reported  to  consist almost entirely of malignant leukemic cells  7 days after 
inoculation (9).  If the splenic L1210 cells bore tumor-specific antigens (TSA) 
on their surfaces, a  significant MLR might result when the tumor cells  were 
cultured  together with normal  spleen cells  of the  same  strain  as the  tumor 
cells,  i.e., DBA/2. In fact, however, the contrary result was observed: spleen 
cells  from  tumor-bearing  F1  mice  reacted  vigorously to  mitomycin-treated, 
normal parental cells.  This response was specific  both for the tumor-bearing 
spleen cells  (BDFt) and for the parental cells from the Strain from which the 
tumor was derived (DBA/2). Normal BDF1 spleen cells  reacted only weakly 
against DBA/2 cells, and BDFt spleen cells reacted only weakly against cells 
from the other parent (C57B1/6). 
The obvious question arising from the experiments reported here is: which 
cell type, normal or malignant, is responsible for the suggestive antiself reac- 
tivity which has been revealed? This important differentiation of reactive cell 
type  might  be  answered  by  experiments  currently  in  progress  using  solid 228  REACTION  OF ]F  1 CELLS  AGAINST  PARENTAL  CELLS 
L1210  tumors induced by s.c. injection of L1210 cells.  However, since both 
normal and malignant cells possess H-2  a antigens, neither cell type would be 
expected to react against normal DBA/2 cells which are also H-2  ~ antigenically. 
Thus,  the end result would be the same, no matter which type is involved, 
i.e., a  tumor-indnced antiself reactivity which presumably would weaken the 
host's attack against the tumor. A better experiment to illustrate this auto- 
immune-like process  would employ spleen  cells  from  tumor-bearing DBA/2 
mice and normal DBA/2 spleen cells in MLR. This type of experiment would 
eliminate  any  complications  resulting  from  the  use  of  semisyngeneic cells, 
as described in this report,  by using an entirely syngeneic system. It would 
also be necessary to determine if the same type of reactions occur using autolo- 
gous cells. The former experimental system will be described in the next paper 
of this series,  and the results will be discussed in terms of the necessary caution 
which must be exercised in interpreting experiments concerned with the im- 
munology of transplantable tumors. 
SITMMARY 
The  establishment of  an  intimate connection between  autoimmunity and 
neoplasia  would  require  the  demonstration  of  an  experimentally  induced, 
tumor-dependent autoimmune process.  For this reason, we have studied cellu- 
lar  immune  reactions  of  mice  bearing  a  transplantable  leukemia  (LI210). 
Spleen cells from hybrid BDF1 mice bearing the L1210 tumor (BDFt) reacted 
vigorously in mixed lymphocyte culture with mitomycin-treated, normal spleen 
cells  from mice of the parental  strain from which the LI210  tumor was de- 
rived  (DBA/2).  Spleen cells from nontumor-bearing BDFI mice reacted only 
weakly with these parental cells. The BDFt cells likewise did not respond when 
cultured with mitomycin-treated spleen  cells  from the  other parental  strain 
(C57B1/6).  The vigorous mixed lymphocyte reaction  (MLR)  by BDFt cells 
against normal palental cells of the same strain as the tumor was not due to a 
double exposure of the reacting cells to histocompatibility antigens shared by 
tumor cells and normal parental cells. The response of cells from tumor-bearing 
FI mice against normal parental ceils  seen in these experiments suggests the 
possibility of the induction of an autoimmune-like process against host lympho- 
cytes by spleen cells  from leukemic mice. Theoretically such a  phenomenon 
would considerably reduce  an  animal's ability to mount an immune  attack 
against malignant cells. 
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